Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 3 |
| Cancer Supportive Care Products Market: Introduction | 12 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Cancer Supportive Care Products Market: Market Overview | 13 | 15 |
| Revenue | 13 | 1 |
| Average Annual Cost of Therapy | 14 | 1 |
| Therapeutic Segmentation | 15 | 1 |
| Geographic Segmentation | 16 | 4 |
| Generic Share in the Cancer Supportive Care Products Market | 20 | 1 |
| Drivers and Restraints of Cancer Supportive Care Products Market | 21 | 1 |
| Drivers | 21 | 1 |
| Growth in the Markets of Bone Metastases, Cancer Pain and Oral Mucositis and Dry Mouth | 21 | 1 |
| Increase in Cancer Prevalence | 21 | 1 |
| High Unmet Need, Specifically With Respect to Drug Efficacy and Safety | 21 | 1 |
| Restraints | 22 | 1 |
| Patent Expiry of Leading Drugs in Major Cancer Supportive Care Products Markets | 22 | 1 |
| Weak Pipeline with Very Few Promising Molecules | 22 | 1 |
| Increased Uptake of Combination Therapies for Cancer that Reduces the Adverse Events Related to Chemotherapy | 22 | 1 |
| Unmet Needs | 23 | 1 |
| Efficacy | 23 | 1 |
| Safety | 23 | 1 |
| Price | 23 | 1 |
| Major Drug Classes | 24 | 1 |
| Anti-infectives (Oral Mucositis) | 24 | 1 |
| Anti-emetics (CINV) | 24 | 1 |
| Bisphosphonates (Bone Metastases) | 25 | 1 |
| Erythropoietin Stimulating Agents (CIA) | 25 | 1 |
| Granulocyte Colony Stimulating Factors (CINP) | 26 | 1 |
| Opioid Analgesics (Cancer Pain and Bone Metastases) | 26 | 1 |
| NSAIDs (Cancer Pain and Bone Metastases) | 26 | 1 |
| Monoclonal Antibodies (Bone Metastases) | 27 | 1 |
| Cancer Supportive Care Products Market: Therapeutic Landscape | 28 | 61 |
| Oral Mucositis and Dry Mouth Market | 28 | 1 |
| Introduction | 28 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| Treatment Usage Patterns | 31 | 1 |
| Prevalence Population | 32 | 1 |
| Prescription Population | 33 | 1 |
| Drivers for the Oral Mucositis and Dry Mouth Market | 33 | 1 |
| High Unmet Need | 33 | 1 |
| Restraints for the Oral Mucositis and Dry Mouth Market | 34 | 1 |
| Patent Expiries of Kepivance | 34 | 1 |
| Availability of Alternate Non-Pharmacological Treatment Options | 34 | 1 |
| Geographical Segmentation | 34 | 4 |
| Chemotherapy Induced Nausea and Vomiting Market | 38 | 1 |
| Introduction | 38 | 2 |
| Revenue | 40 | 1 |
| Annual Cost of Therapy | 41 | 1 |
| Treatment Usage Patterns | 42 | 1 |
| Prevalence Population | 43 | 1 |
| Prescription Population | 44 | 1 |
| Drivers for the Chemotherapy Induced Nausea and Vomiting Market | 44 | 1 |
| Increase Uptake of Novel Anti-Emetics Such As Emend | 44 | 1 |
| Increase in Cancer Prevalence | 44 | 1 |
| Restraints for the Chemotherapy Induced Nausea and Vomiting Market | 45 | 1 |
| Patent Expiry of Leading Anti-Emetics Such As Aloxi, Emend and Anzemet | 45 | 1 |
| Better Chemotherapy Drugs with Low or Minimal Emetic Risk | 45 | 1 |
| Geographical Landscape | 46 | 3 |
| Cancer Pain Market | 49 | 1 |
| Introduction | 49 | 1 |
| Revenue | 49 | 1 |
| Annual Cost of Therapy | 50 | 1 |
| Treatment Usage Patterns | 51 | 1 |
| Diseased Population | 52 | 1 |
| Treatment Seeking Population | 53 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 55 | 1 |
| Drivers for the Cancer Pain Market | 56 | 1 |
| Increasing Treatment Seeking, Diagnosis and Prescription Rate Will Drive the Market | 56 | 1 |
| New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration | 56 | 1 |
| Restraints for the Cancer Pain Market | 56 | 1 |
| Concerns over the Risks of Addiction Related to Drug Therapy Will Affect the Prescription Rate | 56 | 1 |
| Geographical Landscape | 57 | 3 |
| Chemotherapy Induced Anemia Market | 60 | 1 |
| Introduction | 60 | 1 |
| Revenue | 60 | 2 |
| Annual Cost of Therapy | 62 | 1 |
| Treatment Usage Patterns | 63 | 1 |
| Prevalence Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Drivers for the Chemotherapy Induced Anemia Market | 66 | 1 |
| Greater Efficacy of Combination Therapies (Erythropoietins and Iron IVs) | 66 | 1 |
| High Unmet Need in Terms of Drug Safety | 66 | 1 |
| Restraints for the Chemotherapy Induced Anemia Market | 66 | 1 |
| Restrictions on the Use of Erythropoietins | 66 | 1 |
| Declining Incidence of CIA in the Chemotherapy Patient Population | 66 | 1 |
| Entry of Biosimilars | 66 | 1 |
| Geographical Landscape | 67 | 3 |
| Chemotherapy Induced Neutropenia Market | 70 | 1 |
| Introduction | 70 | 1 |
| Revenue | 71 | 1 |
| Annual Cost of Therapy | 72 | 1 |
| Treatment Usage Patterns | 73 | 1 |
| Prevalence Population | 74 | 1 |
| Prescription Population | 75 | 1 |
| Drivers for the Chemotherapy Induced Neutropenia Market | 76 | 1 |
| Higher Uptake of G-CSFs | 76 | 1 |
| Increased Affordability Due to Entry of Biosimilars | 76 | 1 |
| Restraints for the Chemotherapy Induced Neutropenia Market | 76 | 1 |
| Patent Expiries of Leading G-CSFs | 76 | 1 |
| Weak Pipeline | 76 | 1 |
| Geographical Landscape | 77 | 2 |
| Bone Metastases Market | 79 | 1 |
| Introduction | 79 | 1 |
| Revenue | 80 | 1 |
| Annual Cost of Therapy | 81 | 1 |
| Treatment Usage Patterns | 82 | 1 |
| Prevalence Population | 83 | 1 |
| Prescription Population | 84 | 1 |
| Drivers for the Bone Metastases Market | 85 | 1 |
| Increased Uptake of Monoclonal Antibodies such as Denosumab | 85 | 1 |
| Increasing Prevalence of Cancer and Resulting Population Suffering From Bone Metastases | 85 | 1 |
| Restraints for the Bone Metastases Market | 85 | 1 |
| Patent Expiry of Leading Bisphosphonates such as Zometa and Boniva | 85 | 1 |
| Geographical Landscape | 86 | 3 |
| Cancer Supportive Care Products Market: Geographical Landscape | 89 | 10 |
| The US | 89 | 1 |
| Revenue | 89 | 1 |
| Average Annual Cost of Therapy | 90 | 1 |
| Therapeutic Segmentation | 91 | 1 |
| Top Five Countries of Europe | 92 | 1 |
| Revenue | 92 | 1 |
| Average Annual Cost of Therapy | 93 | 1 |
| Therapeutic Segmentation | 94 | 1 |
| Geographic Segmentation | 95 | 1 |
| Japan | 96 | 1 |
| Revenue | 96 | 1 |
| Average Annual Cost of Therapy | 97 | 1 |
| Therapeutic Segmentation | 98 | 1 |
| Cancer Supportive Care Products Market: Pipeline Analysis | 99 | 14 |
| Introduction | 99 | 2 |
| Research and Development Pipeline Oral Mucositis and Dry Mouth | 101 | 1 |
| Research and Development Pipeline Chemotherapy Induced Nausea and Vomiting | 102 | 1 |
| Research and Development Pipeline Cancer Pain | 103 | 1 |
| Research and Development Pipeline Chemotherapy Induced Anemia | 104 | 1 |
| Research and Development Pipeline Chemotherapy Induced Neutropenia | 105 | 1 |
| Research and Development Pipeline Bone Metastases | 106 | 1 |
| Profiles of Promising Drugs in the Cancer Supportive Care Products Market | 107 | 1 |
| Xgeva/Prolia (denosumab) Bone Metastases | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| Clinical Study Details | 107 | 1 |
| Alpharadin Bone Metastases | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| Clinical Study Details | 108 | 1 |
| MAXY-G34 Chemotherapy Induced Neutropenia | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| Clinical Study Details | 109 | 1 |
| Lactermin Oral Mucositis | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 110 | 1 |
| Clinical Study Details | 110 | 1 |
| Xen2174 Cancer Pain | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| Clinical Study Details | 111 | 1 |
| Tectin Cancer Pain | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| Clinical Study Details | 111 | 1 |
| NasalFent Cancer Pain | 112 | 1 |
| Introduction | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| Clinical Study Details | 112 | 1 |
| Cancer Supportive Care Products Market: Competitive Landscape | 113 | 11 |
| Market Share Analysis | 113 | 1 |
| Competitive Profiling | 114 | 1 |
| Amgen | 114 | 1 |
| Business Description | 114 | 1 |
| Products Portfolio | 114 | 1 |
| Pipeline Portfolio | 115 | 1 |
| SWOT Analysis | 116 | 1 |
| Johnson &Johnson | 116 | 1 |
| Business Description | 116 | 1 |
| Products Portfolio | 117 | 1 |
| Pipeline Portfolio | 117 | 1 |
| SWOT Analysis | 118 | 1 |
| F. Hoffmann-La Roche | 118 | 1 |
| Business Description | 118 | 1 |
| Products Portfolio | 119 | 1 |
| Pipeline Portfolio | 119 | 1 |
| SWOT Analysis | 119 | 1 |
| Novartis | 120 | 1 |
| Business Description | 120 | 1 |
| Products Portfolio | 120 | 1 |
| Pipeline Portfolio | 121 | 1 |
| SWOT Analysis | 121 | 1 |
| Pfizer | 122 | 1 |
| Business Description | 122 | 1 |
| Products Portfolio | 122 | 1 |
| Pipeline Portfolio | 123 | 1 |
| SWOT Analysis | 123 | 1 |
| Cancer Supportive Care Products Market: Deals Landscape | 124 | 7 |
| M&A and Licensing Agreements | 124 | 1 |
| Deals by Year | 124 | 1 |
| Deals by Deal Type | 125 | 1 |
| Deals by Indication | 126 | 1 |
| Deals by Value ($m) | 127 | 1 |
| Deals by Geography | 128 | 1 |
| Major Acquisitions in the Cancer Supportive Care Products Market | 128 | 1 |
| Amgen Acquires Dompe Biotec | 128 | 1 |
| Major Licensing Agreements in the Cancer Supportive Care Products Market | 129 | 1 |
| Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca | 129 | 1 |
| Celgene Enters Into Co-Development Agreement with Acceleron Pharma | 129 | 1 |
| Amgen Enters Into Co-Development Agreement with Takeda Pharmaceutical | 130 | 1 |
| Algeta Signs Licensing Agreement with Bayer | 130 | 1 |
| Amgen Enters Into License Agreement with Ortho-McNeil-Janssen | 130 | 1 |
| Cancer Supportive Care Products Market: Appendix | 131 | 7 |
| Market Definitions | 131 | 1 |
| Abbreviations | 131 | 2 |
| Research Methodology | 133 | 4 |
| Coverage | 133 | 1 |
| Primary Research | 134 | 1 |
| Forecasts | 134 | 1 |
| Epidemiology-based Forecasting | 134 | 2 |
| Expert Panel Validation | 136 | 1 |
| Contact Us | 137 | 1 |
| Disclaimer | 137 | 1 |
| Sources | 137 | 1 |